Sullivan Timothy Eugene 4
4 · Apellis Pharmaceuticals, Inc. · Filed Oct 23, 2025
Insider Transaction Report
Form 4
Sullivan Timothy Eugene
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-10-21$28.03/sh−10,000$280,300→ 110,936 total - Exercise/Conversion
Common Stock
2025-10-21$10.03/sh+10,000$100,300→ 120,936 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-21−10,000→ 232,903 totalExercise: $10.03Exp: 2027-10-18→ Common Stock (10,000 underlying)
Holdings
- 60,396(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025.
- [F2]The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- [F3]This option was granted on October 18, 2017 and fully vested.